Literature DB >> 20732754

Failure rates and patterns of recurrence in patients with resected N1 non-small-cell lung cancer.

John M Varlotto1, Laura Nyshel Medford-Davis, Abram Recht, John C Flickinger, Eric Schaefer, Malcolm M DeCamp.   

Abstract

PURPOSE: To examine the local and distant recurrence rates and patterns of failure in patients undergoing potentially curative resection of N1 non-small-cell lung cancer. METHODS AND MATERIALS: The study included 60 consecutive unirradiated patients treated from 2000 to 2006. Median follow-up was 30 months. Failure rates were calculated by the Kaplan-Meier method. A univariate Cox proportional hazard model was used to assess factors associated with recurrence.
RESULTS: Local and distant failure rates (as the first site of failure) at 2, 3, and 5 years were 33%, 33%, and 46%; and 26%, 26%, and 32%, respectively. The most common site of local failure was in the mediastinum; 12 of 18 local recurrences would have been included within proposed postoperative radiotherapy fields. Patients who received chemotherapy were found to be at increased risk of local failure, whereas those who underwent pneumonectomy or who had more positive nodes had significantly increased risks of distant failure.
CONCLUSIONS: Patients with resected non-small-cell lung cancer who have N1 disease are at substantial risk of local recurrence as the first site of relapse, which is greater than the risk of distant failure. The role of postoperative radiotherapy in such patients should be revisited in the era of adjuvant chemotherapy.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20732754     DOI: 10.1016/j.ijrobp.2010.05.022

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Surveillance Practice Patterns after Curative Intent Therapy for Stage I Non-Small-Cell Lung Cancer in the Medicare Population.

Authors:  Christopher T Erb; Kevin W Su; Pamela R Soulos; Lynn T Tanoue; Cary P Gross
Journal:  Lung Cancer       Date:  2016-07-19       Impact factor: 5.705

Review 2.  Evidence-based recommendations of postoperative radiotherapy in lung cancer from Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).

Authors:  A Gómez; J A González; F Couñago; C Vallejo; F Casas; N Rodríguez de Dios
Journal:  Clin Transl Oncol       Date:  2015-08-18       Impact factor: 3.405

3.  Risk factors for local and regional recurrence in patients with resected N0-N1 non-small-cell lung cancer, with implications for patient selection for adjuvant radiation therapy.

Authors:  J L Lopez Guerra; D R Gomez; S H Lin; L B Levy; Y Zhuang; R Komaki; J Jaen; A A Vaporciyan; S G Swisher; J D Cox; Z Liao; D C Rice
Journal:  Ann Oncol       Date:  2012-09-20       Impact factor: 32.976

Review 4.  The Role of PET/CT Molecular Imaging in the Diagnosis of Recurrence and Surveillance of Patients Treated for Non-Small Cell Lung Cancer.

Authors:  Julio Francisco Jiménez-Bonilla; Remedios Quirce; I Martínez-Rodríguez; María De Arcocha-Torres; José Manuel Carril; Ignacio Banzo
Journal:  Diagnostics (Basel)       Date:  2016-09-30

5.  PTEN mutant non-small cell lung cancer require ATM to suppress pro-apoptotic signalling and evade radiotherapy.

Authors:  Oliver Hartmann; Michaela Reissland; Thomas Fischer; Cristian Prieto-Garcia; Kevin Klann; Nikolett Pahor; Christina Schülein-Völk; Apoorva Baluapuri; Bülent Polat; Arya Abazari; Elena Gerhard-Hartmann; Hans-Georg Kopp; Frank Essmann; Mathias Rosenfeldt; Christian Münch; Michael Flentje; Markus E Diefenbacher
Journal:  Cell Biosci       Date:  2022-04-27       Impact factor: 9.584

6.  Risk factors for locoregional recurrence in patients with resected N1 non-small cell lung cancer: a retrospective study to identify patterns of failure and implications for adjuvant radiotherapy.

Authors:  Chengcheng Fan; Shugeng Gao; Zhouguang Hui; Jun Liang; Jima Lv; Xiaozhen Wang; Jie He; Luhua Wang
Journal:  Radiat Oncol       Date:  2013-12-09       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.